Zurcher Kantonalbank Zurich Cantonalbank Has $718,000 Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 34.1% in the fourth quarter, HoldingsChannel reports. The firm owned 15,584 shares of the biopharmaceutical company’s stock after acquiring an additional 3,961 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Xenon Pharmaceuticals were worth $718,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of XENE. Exchange Traded Concepts LLC increased its stake in shares of Xenon Pharmaceuticals by 22.2% in the third quarter. Exchange Traded Concepts LLC now owns 3,967 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 720 shares in the last quarter. Assetmark Inc. grew its holdings in Xenon Pharmaceuticals by 21.5% during the 3rd quarter. Assetmark Inc. now owns 7,103 shares of the biopharmaceutical company’s stock worth $243,000 after acquiring an additional 1,258 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Xenon Pharmaceuticals by 98.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,651 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 818 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Xenon Pharmaceuticals by 13.5% in the third quarter. Jennison Associates LLC now owns 213,823 shares of the biopharmaceutical company’s stock worth $7,304,000 after acquiring an additional 25,432 shares during the last quarter. Finally, Teacher Retirement System of Texas lifted its position in shares of Xenon Pharmaceuticals by 5.5% during the third quarter. Teacher Retirement System of Texas now owns 14,418 shares of the biopharmaceutical company’s stock worth $493,000 after purchasing an additional 746 shares in the last quarter. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Price Performance

Shares of XENE stock opened at $42.73 on Tuesday. The stock has a market cap of $3.22 billion, a PE ratio of -15.71 and a beta of 1.15. The stock has a 50-day moving average of $43.83 and a 200-day moving average of $41.16. Xenon Pharmaceuticals Inc. has a one year low of $27.99 and a one year high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.12. Xenon Pharmaceuticals’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.57) earnings per share. As a group, research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.04 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on XENE shares. Wedbush raised their price target on shares of Xenon Pharmaceuticals from $46.00 to $51.00 and gave the company an “outperform” rating in a report on Friday, March 1st. Citigroup started coverage on Xenon Pharmaceuticals in a research note on Thursday, January 4th. They issued a “buy” rating and a $62.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price target on shares of Xenon Pharmaceuticals in a research note on Wednesday, April 10th. Needham & Company LLC reiterated a “buy” rating and issued a $62.00 price objective on shares of Xenon Pharmaceuticals in a research report on Friday, April 12th. Finally, Bank of America upped their target price on shares of Xenon Pharmaceuticals from $52.00 to $56.00 and gave the company a “buy” rating in a research report on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $59.44.

Insiders Place Their Bets

In other news, EVP Sherrington Robin sold 7,137 shares of the stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $46.28, for a total transaction of $330,300.36. Following the completion of the sale, the executive vice president now owns 8,398 shares of the company’s stock, valued at $388,659.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Sherrington Robin sold 7,137 shares of the stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $46.28, for a total transaction of $330,300.36. Following the completion of the transaction, the executive vice president now directly owns 8,398 shares in the company, valued at $388,659.44. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Steven Gannon sold 13,000 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $46.28, for a total transaction of $601,640.00. Following the completion of the sale, the director now owns 2,000 shares in the company, valued at $92,560. The disclosure for this sale can be found here. Corporate insiders own 5.43% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.